Fatih Uckun, M.D., Ph.D.
Equibles does not estimate personal net worth.
About Fatih Uckun, M.D., Ph.D.
Oncotelic Therapeutics, Inc. reported in an 8-K filed March 2, 2023 that Fatih Uckun, M.D., Ph.D. resigned as Chief Medical Officer, effective February 28, 2023.
“On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer ("CMO") of Oncotelic Therapeutics, Inc. (the "Company"), notified the Company of his resignation as the Company's CMO, effective February 28, 2023.”
Affiliation history
-
2022-05-01–2020-01-06